NASD · Healthcare · Biotechnology · USA
Cytokinetics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Cytokinetics discovers and develops small molecule drugs that modulate muscle function for treating cardiovascular and neuromuscular diseases. The company's first approved product is MYQORZO, a cardiac myosin inhibitor authorized by the FDA, European Commission, and China for treating obstructive hypertrophic cardiomyopathy. The company maintains a pipeline of investigational candidates in various development stages.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Cytokinetics Inc stock.
Overvalued: intrinsic value $1.04 per share, market price $51.65, margin of safety -4849.9% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $1.04; the price of $51.65 is 4850% above that value.
17 more funds hold it; the full list is part of the paid plan.
125 more in this industry show a wider margin of safety.
CYTK is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $1.04; the price of $51.65 is 4850% above that value.
$1.04 per share (as of the 2026-11-17 close), against a market price of $51.65. That is a margin of safety of -4849.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.